NICE UK Positive for Blincyto

if: i) the leukaemia is minimal residual disease-negative; ii) it is used at the start of consolidation treatment; iii) the company provides it according to the commercial arrangement. This recommendation is not intended to affect treatment with blinatumomab with chemotherapy that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS healthcare professional consider it appropriate to stop. Why the committee made these recommendations - Usual consolidation treatment for Philadelphia-chromosome-negative CD19-positive B-cell precursor ALL that is minimal residual disease-negative is chemotherapy. For this evaluation, the company asked for blinatumomab to be considered with chemotherapy and only for ALL that is minimal residual disease-negative at the start of consolidation treatment. This does not include everyone who it is licensed for. Clinical trial evidence shows that blinatumomab with chemotherapy increases how long people live and how long they have before their ALL relapses compared with chemotherapy alone. The cost-effectiveness estimates are within the range that NICE considers an acceptable use of NHS resources. So, blinatumomab with chemotherapy can be used.

Blinatumomab with chemotherapy must be funded by the NHS in England and Wales to treat Philadelphia-chromosome-negative CD19-positive B-cell precursor ALL in adults that is minimal residual disease-negative at the start of consolidation treatment, if it is considered the most suitable treatment option. Blinatumomab with chemotherapy must be funded in England within 90 days of final publication of this guidance. There is enough evidence to show that blinatumomab with chemotherapy provides benefits and value for money, so it can be used routinely across the NHS.